$272.70
Value $657B
JNJ and OPCH stock compared: price, dividend, valuation and results, from SEC filings.
$272.70
Value $657B
$31.71
Value $5.0B
Johnson & Johnson (JNJ) has a market value of $657B and Option Care Health (OPCH) $5.0B. Over the last year, with dividends, JNJ moved +39.7% and OPCH +12.8%. The P/E is 40.8 for JNJ and 23.1 for OPCH. Dividend yield: JNJ 1.94%, OPCH none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
JNJ$657B
OPCH$5.0B
JNJ is 132 times OPCH
Revenue, 12 months
JNJ$99.3B
OPCH$5.8B
JNJ is 17 times OPCH
Net income, 12 months
JNJ$16.1B
OPCH$215M
JNJ is 75 times OPCH
Operating margin
JNJ–
OPCH5.9%
ROIC
JNJ12.4%
OPCH9.9%
2.5 points apart
P/E
JNJ40.8
OPCH23.1
JNJ is 1.8 times OPCH
Dividend yield
JNJ1.9%
OPCH0.0%
1.9 points apart
5-year return
JNJ+92.0%
OPCH+19.6%
72.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
JNJ+92.0%
OPCH+19.6%
| Period | JNJWith dividends | OPCHWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +39.7%Price +36.6% | +12.8%Price +12.8% |
| 3 years since November 17, 2023 | +98.2%+25.6% a yearPrice +82.1% | +8.2%+2.7% a yearPrice +8.2% |
| 5 years since November 17, 2021 | +92.0%+13.9% a yearPrice +67.0% | +19.6%+3.6% a yearPrice +19.6% |
| 10 years since November 18, 2016 | +208.0%+11.9% a yearPrice +136.4% | +491.6%+19.5% a yearPrice +491.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
JNJJohnson & JohnsonOPCHOption Care Health
| Price | $272.70 | $31.71 |
|---|---|---|
| Market value | $657B | $5.0B |
| Enterprise value (EV) | $685B | $5.8B |
| P/E | 40.8 | 23.1 |
| P/E, 5-year median | 21.9 | 25.1 |
| P/B | 8.1 | 3.8 |
| EV/EBIT | 38.6 | 17.2 |
| Free cash flow yield | 3.1% | 5.7% |
| Revenue, 12 months | $99.3B | $5.8B |
|---|---|---|
| Net income, 12 months | $16.1B | $215M |
| Free cash flow, 12 months | $20.6B | $282M |
| Earnings per share, 12 months | $6.59 | $1.38 |
| Revenue growth, year on year | 6.1% | 13.0% |
| Revenue growth a year, past | +2.7%over 5 years | +13.3%over 5 years |
| EPS growth a year, past | +14.9%over 5 years | – |
| Gross margin | 67.6% | 19.1% |
|---|---|---|
| Operating margin | – | 5.9% |
| Net margin | 16.2% | 3.7% |
| ROIC | 12.4% | 9.9% |
| ROE | 19.7% | 16.3% |
| Cash | $17.2B | $299M |
|---|---|---|
| Total debt | $44.7B | $1.3B |
| Net debt / EBITDA | 1.1 | 2.1 |
| Interest cover | 18.0× | 6.4× |
| Dividend yield | 1.9% | – |
|---|---|---|
| Dividend per share, 12 months | $5.28 | – |
| Dividend growth a year, past | +5.3%over 5 years | – |
| Buyback yield | 0.9% | 6.3% |
| Shareholder yield | 2.9% | 6.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($657B) is about 132.5 times Option Care Health ($5.0B), at today's prices.
Since November 18, 2016, JNJ's price moved +136.4% and OPCH's +491.6%. With dividends: JNJ +208.0% (+11.9% a year), OPCH +491.6% (+19.5% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.94% for Johnson & Johnson and none for Option Care Health. Over the last twelve months they paid $5.28 and – per share.
At today's price, the P/E is 40.8 for JNJ and 23.1 for OPCH. The median of the last five years was 21.9 and 25.1, which shows where each stands against its own past.
Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 3.7% for Option Care Health, and the operating margin – and 5.9%. Revenue was $99.3B and $5.8B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.